scPharmaceuticals (scPharmaceuticals) Additional Paid-In Capital : $320.02 Mil(As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals Additional Paid-In Capital?

scPharmaceuticals's quarterly additional paid-in capital increased from Sep. 2023 ($316.68 Mil) to Dec. 2023 ($318.56 Mil) and increased from Dec. 2023 ($318.56 Mil) to Mar. 2024 ($320.02 Mil).

scPharmaceuticals's annual additional paid-in capital increased from Dec. 2021 ($246.17 Mil) to Dec. 2022 ($298.93 Mil) and increased from Dec. 2022 ($298.93 Mil) to Dec. 2023 ($318.56 Mil).

scPharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for scPharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Additional Paid-In Capital Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

180.82

243.83

246.17

298.93

318.56

scPharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															313.54	315.33	316.68	318.56	320.02

scPharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

scPharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals (scPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

2SX:Germany

Address

2400 District Avenue, Suite 310, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar	director	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker	director, officer: President and CEO	INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham	director	C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	other: See Remarks	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	other: See Remarks	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes	officer: See Remarks	C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803